ライフサイエンスコーパス: invasive fungal infection

1 n blood test may assist is the definition of invasive fungal infection.

2 gitel assay may be most useful for excluding invasive fungal infection.

3 l activity and efficacy in a murine model of invasive fungal infection.

4 omised patients with detrimental immunity to invasive fungal infection.

5 other clinical or laboratory indications of invasive fungal infection.

6 Forty-five patients (11%) developed invasive fungal infection.

7 alized patients and the most common cause of invasive fungal infection.

8 al for the care of patients with a suspected invasive fungal infection.

9 with proven/probable IA and controls with no invasive fungal infection.

10 cally ill patients, often without documented invasive fungal infection.

11 ptimised imaging for patients with suspected invasive fungal infection.

12 severe colitis and are highly susceptible to invasive fungal infection.

13 ystemic antifungal therapy had no documented invasive fungal infection.

14 , including 100 without and 54 with a proven invasive fungal infection.

15 ork for developing FTase inhibitors to treat invasive fungal infections.

16 of epidemiology, prevention and treatment of invasive fungal infections.

17 ce of immunogenetics in conferring risks for invasive fungal infections.

18 singly been reported as the causes of severe invasive fungal infections.

19 f surgical intensive care unit patients with invasive fungal infections.

20 ld be used in unison to aid the detection of invasive fungal infections.

21 lture-based methods may aid the diagnosis of invasive fungal infections.

22 glucan (BG) and is intended for diagnosis of invasive fungal infections.

23 B for the prevention and early treatment of invasive fungal infections.

24 w approaches to prevent, diagnose, and treat invasive fungal infections.

25 d offer new therapeutic strategies to combat invasive fungal infections.

26 cin B or liposomal amphotericin B to prevent invasive fungal infections.

27 reatment and prevention of clinically occult invasive fungal infections.

28 s therapy, particularly for the treatment of invasive fungal infections.

29 he bloodstream is a critical step leading to invasive fungal infections.

30 ious toxicity indicated by the lower rate of invasive fungal infections.

31 r early diagnosis and clinical management of invasive fungal infections.

32 us' potential link to cause disseminated and invasive fungal infections.

33 ended as first-line therapy for treatment of invasive fungal infections.

34 o and highly efficacious in animal models of invasive fungal infections.

35 of agents available to treat drug-resistant invasive fungal infections.

36 t advances in the diagnosis and treatment of invasive fungal infections.

37 future prospects of a human vaccine against invasive fungal infections.

38 inical courses were not consistent with true invasive fungal infections.

39 nt of aspergillosis, mucormycosis, and other invasive fungal infections.

40 ing the clinical management of patients with invasive fungal infections.

41 suppressive drugs have a higher incidence of invasive fungal infections.

42 thelium could serve as a portal of entry for invasive fungal infections.

43 ies, but data are lacking from patients with invasive fungal infections.

44 medication used for prophylaxis or to treat invasive fungal infections.

45 lopment of Spt14 inhibitors for treatment of invasive fungal infections.

46 l yeast Candida albicans is a major cause of invasive fungal infections.

47 that this test has value in the diagnosis of invasive fungal infections.

48 ing an increasing variety of superficial and invasive fungal infections.

49 ul for at least the presumptive diagnosis of invasive fungal infections.

50 ying immunity to mucocutaneous as opposed to invasive fungal infections.

51 ] for 5 vs none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumo

52 ] for 5 vs none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumo

53 ral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79

54 fungal infections (1.31; 95% CI, .46-3.72), invasive fungal infections (2.85; .68-11.91), P. jirovec

55 In this cohort, the incidence of invasive fungal infections (36% vs. 7%, P=0.0007) and in

56 incidence of first grade 2 to 3 bacterial or invasive fungal infection (37% vs 57%; P = .027), and sp

57 Invasive fungal infections, accompanied by high rates of

58 (relative effect estimate >= 2) to any early invasive fungal infections across all solid organ transp

59 s using factors known to affect the risk for invasive fungal infection after hematopoietic stem-cell

60 tomegalovirus infection is a risk factor for invasive fungal infection after transplantation, we have

61 han fluconazole for long-term prophylaxis of invasive fungal infections after allogeneic hematopoieti

62 an independently significant risk factor for invasive fungal infections after liver transplantation.

63 The mortality attributable to invasive fungal infections among patients with mold infe

64 sidered clinically relevant (2 isolates from invasive fungal infection and 13 isolates from cutaneous

65 one similarly enhanced the susceptibility to invasive fungal infection and systemic bacterial co-infe

66 recently been approved for the prevention of invasive fungal infection and the treatment of esophagea

67 Six patients (5%) developed invasive fungal infections and 5 patients (4%) had life-

68 ibute to the ability of these fungi to cause invasive fungal infections and allergic diseases.

69 risk factors for the primary outcome of any invasive fungal infections and invasive candidiasis or i

70 at engraftment is associated with more early invasive fungal infections and more late CMV disease res

71 rates (>98.0%) against Candida isolates from invasive fungal infections and showed potent activity ag

72 ng many serious infectious diseases, such as invasive fungal infections and visceral leishmaniasis, p

73 as an independently significant predictor of invasive fungal infections and was associated with late

74 ungal colonization, prevents superficial and invasive fungal infections, and has no appreciable hepat

75 ls are postulated to provide defense against invasive fungal infection, animal models and human studi

76 Invasive fungal infections are a leading cause of morbid

77 Invasive fungal infections are a major threat for patien

78 Invasive fungal infections are a significant cause of mo

79 Invasive fungal infections are a significant cause of mo

80 Invasive fungal infections are an important cause of mor

81 ronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an important complication

82 Invasive fungal infections are an important infection co

83 Invasive fungal infections are associated with high morb

84 The most common invasive fungal infections are caused by aspergillosis,

85 Invasive fungal infections are emerging diseases that ki

86 , ongoing studies of epidemiologic shifts in invasive fungal infections are important.

87 Invasive fungal infections are increasingly common in th

88 Epidemiologic shifts in invasive fungal infections are likely co-travelers with

89 Shifts in invasive fungal infections are occurring as a consequenc

90 Invasive fungal infections are typically difficult to pr

91 The burden of invasive fungal infections associated with opportunistic

92 of combining C12 or C14 with azoles to treat invasive fungal infections at lower administration doses

93 care unit septic patients without documented invasive fungal infection based on their severity of ill

94 ncidence and characteristics of breakthrough invasive fungal infections (bIFI) in 277 adult patients

95 ucted a retrospective review of breakthrough invasive fungal infections (bIFIs) among adult hematolog

96 eristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high

97 evalence and outcomes of COVID-19-associated invasive fungal infections (CAIFIs) in solid organ trans

98 Invasive fungal infections cause 1.6 million deaths annu

99 Invasive fungal infections cause considerable morbidity

100 this protection breaks down, superficial and invasive fungal infections cause diseases that range fro

101 Invasive fungal infections cause significant morbidity a

102 Invasive fungal infections cause significant morbidity a

103 Mucormycosis is an aggressive invasive fungal infection caused by molds in the order M

104 We describe a case of invasive fungal infection caused by Volvariella volvacea

105 Invasive fungal infections caused by Neosartorya pseudof

106 review the incidence of COVID-19-associated invasive fungal infections caused by these fungi in low-

107 selective defect in the host defense against invasive fungal infection, caused by an impaired phagocy

108 is setting is associated with lower rates of invasive fungal infections compared with placebo or no i

109 A biopsy provided an initial diagnosis of an invasive fungal infection consistent with aspergillosis

110 opulation of patients at risk for developing invasive fungal infections continues to increase.

111 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG)

112 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Mycoses

113 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Nationa

114 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Nationa

115 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Nat

116 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Nat

117 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Nat

118 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group criteria, a

119 ization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National I

120 ization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group/Mycoses Stu

121 Invasive fungal infections developed in 11.1% (2 of 18)

122 This Review aims to describe the invasive fungal infection diagnostic capacity of Europe

123 Eighteen patients (40%) with invasive fungal infection died, and 13 (72%) of these de

124 aration of amphotericin B as prophylaxis for invasive fungal infections, directed toward liver transp

125 Fungal colonization, proven superficial or invasive fungal infection, drug-related side effects, an

126 Invasive fungal infections due to Aspergillus species ha

127 vival, causes of death, and the incidence of invasive fungal infections early (less than 110 days) an

128 ess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no

129 Patients in the invasive fungal infection groups had comparable risk fac

130 Invasive fungal infection has a major impact on the morb

131 Invasive fungal infections have a devastating impact on

132 Invasive fungal infections have a high rate of morbidity

133 Invasive fungal infections have become a major challenge

134 Invasive fungal infections have been described throughou

135 ss this gap, monoclonal antibodies targeting invasive fungal infections have emerged as a promising a

136 ssic culture techniques for the diagnosis of invasive fungal infections have lead to the emergence of

137 Available treatments for invasive fungal infections have limitations, including t

138 ant recipients have the highest incidence of invasive fungal infection; however, no antifungal prophy

139 In multivariate analysis, the risks of invasive fungal infections (HR, 0.59; 95% CI, 0.3-1.0) a

140 prophylaxis is shown to decrease the risk of invasive fungal infection (IFI) after hematopoietic stem

141 Invasive fungal infection (IFI) following liver transpla

142 ntation but also have increased the risk for invasive fungal infection (IFI) in this population.

143 Invasive fungal infection (IFI) is a growing cause of mo

144 Invasive fungal infection (IFI) is a serious threat afte

145 Invasive fungal infection (IFI) is associated with high

146 disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiat

147 recipients with predefined risk factors for invasive fungal infection (IFI), a prospective phase II

148 ainment of complete remission, occurrence of invasive fungal infection (IFI), or for a maximum of 12

149 termine whether empirical micafungin reduces invasive fungal infection (IFI)-free survival at day 28.

150 is the most common pathogen responsible for invasive fungal infection (IFI).

151 d 49 BAL samples from 25 patients with other invasive fungal infections (IFI) (aspergillosis, Pneumoc

152 its inclusion as a mycological criterion of invasive fungal infections (IFI) according to EORTC and

153 Invasive fungal infections (IFI) are a major cause of mo

154 Invasive fungal infections (IFI) occurred in 20 (14.5%)

155 Invasive fungal infections (IFI) remain a serious threat

156 Prompt diagnosis of invasive fungal infections (IFI) remains a challenge.

157 Proven or probable invasive fungal infections (IFI) were evaluated by inten

158 Invasive fungal infections (IFI), particularly those cau

159 irus [HSV/VZV], bloodstream infection [BSI], invasive fungal infection [IFI]) or death occurring afte

160 rus [HSV/VZV], blood stream infection [BSI], invasive fungal infection [IFI]) or death occurring afte

161 in serum has been evaluated in patients with invasive fungal infections (IFIs) and healthy controls a

162 Invasive fungal infections (IFIs) are a major cause of H

163 Invasive fungal infections (IFIs) are common following l

164 Invasive fungal infections (IFIs) are life-threatening c

165 Combat trauma wounds with invasive fungal infections (IFIs) are often polymicrobia

166 gh-profile outbreaks have drawn attention to invasive fungal infections (IFIs) as an increasingly imp

167 Invasive fungal infections (IFIs) cause significant morb

168 The global incidence of invasive fungal infections (IFIs) has increased over the

169 ve data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning

170 The incidence of invasive fungal infections (IFIs) in solid organ transpl

171 Appropriate diagnosis of invasive fungal infections (IFIs) is critical due to the

172 Invasive fungal infections (IFIs) pose a significant thr

173 Treatment of invasive fungal infections (IFIs) remains challenging, b

174 Invasive fungal infections (IFIs) significantly impact m

175 r developments in diagnosis and treatment of invasive fungal infections (IFIs) that complicate cancer

176 Lung transplant recipients commonly develop invasive fungal infections (IFIs), but the most effectiv

177 s in liver transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assess

178 an additional increased risk of non-Candida invasive fungal infections (IFIs).

179 pirical micafungin decreased the rate of new invasive fungal infection in 4 of 128 patients (3%) in t

180 ly, we describe the first case of A. elegans invasive fungal infection in an immunocompromised patien

181 ministered before definitive diagnosis of an invasive fungal infection in critically ill patients wit

182 nd, in some cases, reducing the incidence of invasive fungal infection in critically ill patients.

183 intestinal basidiobolomycosis is an emerging invasive fungal infection in desert regions of the US So

184 Trichosporonosis is an emerging invasive fungal infection in immunosuppressed patients;

185 ective in preventing fungal colonization and invasive fungal infection in infants with birth weights

186 e feasibility of developing vaccines against invasive fungal infection in this fast growing patient p

187 as 8.3% versus 2.1% (P = 0.21), incidence of invasive fungal infections in cases versus controls was

188 s associated with a significant reduction in invasive fungal infections in high-risk liver transplant

189 pecies, Candida albicans, causes half of all invasive fungal infections in humans.

190 Candida albicans is the most common cause of invasive fungal infections in humans.

191 Cryptococcus species are associated with invasive fungal infections in immunosuppressed individua

192 a role in influencing the evolving trends in invasive fungal infections in liver transplant recipient

193 on used for prophylaxis and for treatment of invasive fungal infections in OTRs.

194 The incidence of invasive fungal infections in patients receiving aerosol

195 azole is widely used for prophylaxis against invasive fungal infections in patients undergoing myeloa

196 s with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk he

197 e feasibility of developing vaccines against invasive fungal infections in patients with severe immun

198 lant recipients, accounting for 2% and 8% of invasive fungal infections in recent cohorts of solid-or

199 isk factors exist for the development of any invasive fungal infections in solid organ transplant rec

200 pertained to risk factors for development of invasive fungal infections in solid organ transplant wer

201 We assessed the temporal trends in invasive fungal infections in the context of evolution i

202 t there was a three times lower incidence of invasive fungal infections in the EA (0.5% v 1.5%, P = .

203 e saprophytic molds causing life-threatening invasive fungal infections in the immunocompromised host

204 Invasive fungal infections in the United States are chro

205 last decade as a common cause of mucosal and invasive fungal infection, in large part due to its intr

206 Seventy-one recipients (21.6%) developed invasive fungal infections, including 29 patients (8.8%)

207 lative incidence rates of proven or probable invasive fungal infections, invasive mold infections, in

208 Invasive fungal infection is a serious health threat wit

209 Invasive fungal infection is associated with substantial

210 The diagnosis of an invasive fungal infection is difficult, and the risk fac

211 endent IL-17A production in the lungs during invasive fungal infection is mediated in part by CD11b(+

212 atment administered prior to diagnosis of an invasive fungal infection is not associated with either

213 The utility of molecular diagnostics in invasive fungal infections is discussed.

214 unocompromised populations, the incidence of invasive fungal infections is expected to continue to ri

215 Background: The incidence of invasive fungal infections is increasing in immune-compe

216 The incidence of invasive fungal infections is increasing in immune-compe

217 iddle-income countries, where mortality from invasive fungal infections is still substantial, many lo

218 se within the lung, the primary site of most invasive fungal infections, is unknown.

219 8 institutions in Europe self-assessed their invasive fungal infection management capability.

220 resistance has exacerbated the treatment of invasive fungal infections, most commonly caused by Cand

221 presented preexisting host risk factors for invasive fungal infection (n = 20; 14%).

222 e following: resolution of fever; absence of invasive fungal infection; no discontinuation because of

223 Posttransplant invasive fungal infection occurred in 14.8% (4 of 27; as

224 In the ganciclovir group, more invasive fungal infections occurred (P = .03) and more g

225 Invasive fungal infections occurred in 36% (8 of 22) of

226 Proven invasive fungal infections occurred in 6 of 71 itraconaz

227 dverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12

228 -6 infection was an independent predictor of invasive fungal infections (odds ratio 8.3, 95% confiden

229 itraconazole was still associated with fewer invasive fungal infections (odds ratio, 0.300 [CI, 0.111

230 Isolated invasive fungal infections of unclear cellular basis are

231 Immunosuppressed patients at high risk for invasive fungal infections often have prolonged or repea

232 1.4; 95% confidence interval [CI], 1.1-1.8), invasive fungal infection (OR, 1.3; 95% CI, 1.1-1.5), an

233 The incidence of invasive fungal infections, particularly invasive candid

234 mmune suppression increases the incidence of invasive fungal infections, particularly those caused by

235 Invasive fungal infections pose a major threat to human

236 Invasive fungal infections pose an important threat to p

237 study in 75 marrow transplant patients with invasive fungal infections (primarily Aspergillus or Can

238 rgillus fumigatus, and is a leading cause of invasive fungal infection-related mortality and morbidit

239 Invasive fungal infection remains a serious postoperativ

240 s that describe changes in the likelihood of invasive fungal infections, shifts in types of fungal pa

241 glucocorticoid-induced immunosuppression and invasive fungal infections should assist in earlier reco

242 %]), bloodstream infections (six [16%]), and invasive fungal infections (six [16%]).

243 Although Europe is well prepared to manage invasive fungal infections, some institutions do not hav

244 sis inhibitors and are frontline therapy for invasive fungal infections, such as invasive aspergillos

245 Mucormycosis is a severe emerging invasive fungal infection that occurs as a consequence o

246 is responsible for cryptococcosis, a deadly invasive fungal infection that represents around 220,000

247 ally review the spectrum and presentation of invasive fungal infections that arise in the setting of

248 anagement of transplant patients at risk for invasive fungal infection warrants a high index of suspi

249 Mortality due to bacteremia or invasive fungal infection was higher among D(+)/R(-) (18

250 has been reported in an Iranian family with invasive fungal infections, we also sequenced CARD9 in t

251 ble therapeutic indices for the treatment of invasive fungal infections, we initiated a program to de

252 ebo group; P > 0.2), fewer deaths related to invasive fungal infection were seen in the fluconazole g

253 Treatment-related adverse events and invasive fungal infections were quantitated for 2 months

254 associated with lower rates of mortality and invasive fungal infections when administered before defi

255 versy regarding significant risk factors for invasive fungal infection, which has limited the develop

256 Invasive fungal infections, which pose a serious threat

257 Three patients developed invasive fungal infections while on voriconazole prophyl

258 Mucormycosis is a deadly invasive fungal infection whose characteristics are only

259 ole of this new triazole in the treatment of invasive fungal infections will be better defined.

260 Candidemia is a severe invasive fungal infection with high mortality.

261 Invasive fungal infection with positive growth of fungal

262 iable epidemic of mucormycosis (a rare angio-invasive fungal infection), within the ongoing global co